Search results
Results From The WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Programs such as the Revised National Tuberculosis Control Program are working to reduce TB levels among people receiving public health care. [227] [228] A 2014 EIU-healthcare report finds there is a need to address apathy and urges for increased funding. The report cites among others Lucica Ditui "[TB] is like an orphan.
The goal of tuberculosis elimination is hampered by the lack of rapid testing, short and effective treatment courses, and completely effective vaccine. [2] The WHO as well as the Stop TB Partnership aim for the full elimination of TB by 2050—requiring a 1000-fold reduction in tuberculosis incidence. [ 3 ]
The Stop TB Initiative was established following the meeting of the First Session of the Ad Hoc Committee on the Tuberculosis Epidemic held in London in March 1998. [4] In March 2000 the Stop TB Partnership produced the Amsterdam Declaration to Stop TB, which called for action from ministerial delegations of 20 countries with the highest burden of TB.
Treatment of MDR-TB requires treatment with second-line drugs, usually four or more anti-TB drugs for a minimum of 6 months, and possibly extending for 18–24 months if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. [9] Under ideal program conditions, MDR-TB cure rates can ...
A 2008 study in the Tomsk oblast of Russia, reported that 14 out of 29 (48.3%) patients with XDR-TB successfully completed treatment. [16] In 2018, the WHO reported that the treatment success rate for XDR-TB was 34% for the 2015 cohort, compared to 55% for MDR/RR-TB (2015 cohort), 77% for HIV-associated TB (2016 cohort), and 82% for TB (2016 ...
The Global Fund’s investments have reduced deaths from HIV, tuberculosis, and malaria by 61% since 2002, saving 65 million lives. [25] Recent efforts include lowering the cost of key treatments for drug-resistant TB by 55% and first-line HIV medications by 25%, while introducing a more effective insecticide-treated mosquito net. [26]